Inolimomab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Inolimomab ?
Monoclonal antibody
Type Whole antibody
Source Mouse
Target CD25
Clinical data
Legal status
?
Identifiers
CAS number 152981-31-2 N
ATC code None
Chemical data
Formula ?
 N (what is this?)  (verify)

Inolimomab is a mouse monoclonal antibody developed as an immunosuppressive drug against graft-versus-host disease. Its target is the alpha chain of the interleukin-2 receptor.[1][2]

References[edit]

  1. ^ Piñana JL, Valcárcel D, Martino R, et al. (November 2006). "Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease". Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 12 (11): 1135–41. doi:10.1016/j.bbmt.2006.06.010. PMID 17085306. 
  2. ^ Dartois, C.; Freyer, G.; Michallet, M.; Hénin, E.; You, B.; Darlavoix, I.; Vermot-Desroches, C.; Tranchand, B.; Girard, P. (2007). "Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease". Clinical pharmacokinetics 46 (5): 417–432. doi:10.2165/00003088-200746050-00004. PMC 2760126. PMID 17465640.  edit